CD19 and systemic lupus erythematosus: A phase I clinical study of BCMA-CD19 CAR-T cells in SLE patients showed a marked reduction in anti-Sjögren syndrome B antibody autoantibodies following treatment, suggesting successful elimination of pathogenic antibodies predominantly produced by LLPCs [37].